Newsletter · 2026-09-19 · Ashutosh Agarwal

Pharma's 100% Tariff Clock and Medicaid's Coverage Cliff - Healthcare Policy: Drug Pricing, IRA & Managed Care - Week of September 19, 2026

Healthcare Policy for the week of September 12 to September 19, 2026: a 100% Section 232 tariff on imported patented drugs is set to start at the end of September with exemptions for companies that signed pricing and onshoring deals, H.R.1 puts roughly 400,000 Illinois Medicaid enrollees and 8 to 10 million nationally on course to lose coverage, managed care trades at the lowest multiples of any group that beat as insurers fight their own hospitals, 2027 Star Ratings get harder, and even Cigna cut GLP-1 coverage for its own employees.

Healthcare Policy: Drug Pricing, IRA & Managed Care

Week of September 19, 2026: Pharma's 100% Tariff Clock and Medicaid's Coverage Cliff

Week of September 12–19, 2026

Intro

Two clocks started ticking this week, and both are loud.

The first is a tariff clock: a 100% tax on imported patented drugs is scheduled to switch on at the end of September, up from zero. The second is a coverage clock: the big federal law known as H.R.1 begins pulling millions of people off Medicaid starting October 1, with the biggest changes landing in January. Around those two deadlines, the podcasts this week filled in the texture: why health insurance stocks are suddenly trading like troubled companies, why the government's own quality scorecard for Medicare plans is about to get harder, and why even a health insurer just cut the weight-loss drugs its own employees were asking for.

Below is what people who actually work in this world (operators and insiders) said, kept separate from what commentators and investors (pundits) think it means.

TL;DR

• A 100% tariff on patented, imported medicines is set to begin at the end of September, a jump from zero, and companies that cut side deals with the administration on pricing and building U.S. factories get to skip it. Generics could be pulled in next.
• Medicaid is heading for a coverage cliff. New work-paperwork rules and a doubling of how often people must re-prove eligibility could push roughly 400,000 people off coverage in Illinois alone, and an estimated 8–10 million nationally by 2034, and most enrollees don't yet know the rules are changing.
• Health insurers are being priced like they're in trouble, trading at the lowest valuations of any group that beat expectations, as they fight their own hospitals and doctors, brace for a harder Medicare "Star Ratings" scorecard in 2027, and retreat from paying for pricey GLP-1 weight-loss drugs.

What's New

1. The 100% pharma tariff is days away, and it's a "notable progression" from zero. (Operator/insider)

On PwC's accounting podcast (Sept 17), the firm's trade advisers walked through the new tariff landscape and flagged pharmaceuticals as one of the most far-reaching pieces. A "Section 232" national-security tariff, the same legal tool used on steel and copper, is set to hit imported patented drugs at 100%, "starting on certain products at the end of September."

Why it matters, in their words: "the rate will be a 100% for patented products. So companies that have not gone in and have not made these... commitments, their products that they import will be subject to 100%, which from the pharmaceutical space, previously there were zero tariffs. So the MFN level for pharmaceutical was zero. So this is a very notable progression." ("MFN" here is the plain baseline import rate that has always applied.)

The escape hatch is a private deal. Several drugmakers "went in and said, we will agree to certain MFN pricing... as well as doing onshoring, producing in the U.S." and in exchange negotiated "lower rates or no rate... an exemption from the rates for a period of time", with the terms sitting in public annexes. The advisers also noted the awkward math: because Medicare and Medicaid pay for so many U.S. prescriptions, tariffs raise the government's own drug bill, "a little bit of a perverse outcome." And they flagged a separate "Section 301" investigation that specifically calls out pharma manufacturing in Ireland, Switzerland, Singapore, and Germany, plus open talk of eventually pulling generic drugs into the tariff net too.

2. Medicaid's coverage cliff: 400,000 in Illinois, 8–10 million nationally, and most people don't know yet. (Operator/insider)

On the Becker's Healthcare Podcast (Sept 14), Dr. Erik Mikaitis, CEO of Cook County Health, which runs the largest Medicaid plan in the Chicago area, laid out the timeline under H.R.1 in unusually concrete terms.

• Already happening: enhanced insurance tax subsidies ended in January, and "we've already seen in Illinois over 90,000 people forego their coverage because of increased out-of-pocket expenses."
• October 1: a narrower definition of which immigrants qualify removes about 10,000 people in Illinois: "not just not eligible, they won't be insurable."
• January: working-age adults on Medicaid (19–64, no dependents or disabilities) must prove they are "working, volunteering or in school 80 hours per month," and must re-prove eligibility every six months instead of once a year.

The scary part is how few people know: a recent study he cited found 55% of Medicaid enrollees don't realize the work requirements are coming, and 85% don't realize the paperwork cadence is doubling. His bottom line: "There's early estimates right now that about 400,000 people will lose their coverage just in Illinois. And the numbers I've seen out to... 2034, between 8 and 10 million Medicaid enrollees will lose their coverage across the country." He also noted two hospitals have closed in the Chicago area in the past year, with more struggling, because when people lose coverage and skip preventive care, they show up later in the ER with strokes and heart attacks that cost far more.

3. Health insurers are cheap for a reason: they're at war with their own providers. (Pundit)

The markets podcast Telltales (Sept 14, an AI-produced markets show) framed the split in health care nicely: drugmakers are paying up for future science, while the insurers that already generate cash are being marked down. Managed care names carried "the lowest multiples on anything that gets a beat": CVS at about 15 times free cash flow (on roughly $12 billion of it) and UnitedHealth at about 22.

The reason is in the headlines, not the spreadsheet: CVS is being sued by more hospitals that allege it withheld "340B" discounted-drug payments, the same week it launched a joint product, "Cigna Health Works," routing Cigna benefits into CVS pharmacies and clinics. UnitedHealth faced a September 30 deadline for New York-Presbyterian, the largest hospital system in New York, to go out-of-network for most of its commercial plans unless a deal is reached, and it sold a stake in its Florida WellMed clinics to private-equity firm TPG. As the host put it: "When your providers are suing you, and the largest hospital system in your biggest market is weeks from walking, the market discounts the cash flow instead of extrapolating it. That's the honest version of cheap... What settles it is the network contract, not the multiple."

4. The Medicare "report card" gets harder in 2027, a hidden earnings lever for insurers. (Operator/insider)

Two podcasts dug into Star Ratings, the government's 1-to-5 quality score that decides how much bonus money Medicare Advantage plans collect (higher scores = more money and more enrollees).

On The Astonishing Healthcare Podcast (Sept 18), Judi Health's Jay Tran (VP of clinical/client operations) and pharmacist Angela Kalantarova explained the biggest 2027 change: the "medication therapy management" program moves from a practice measure back to a scored measure. Eligibility was widened so much (the cost threshold to qualify dropped "from over $5,300 to $1,200 a year," and conditions like Alzheimer's, bone disease, arthritis and mental health became "core") that they expect a three-to-four-fold jump in eligible members industry-wide. Translation: plans that ignored this while it didn't count now have to scramble, because in 2027 "everyone's going to care about this."

On Bright Spots in Healthcare (Sept 15), executives from Blue Cross Blue Shield of Michigan, Aetna and MVP added the strategic layer. BCBS Michigan's Vanita Pindolia noted her plan is the "seventh largest MA plan in the nation" with nearly 30% of members in full-risk contracts that now bake Star measures directly into what doctors get paid. Aetna's Charlotta Eriksson said the insurer is "all in on specialty" value-based care (kidney, oncology, now musculoskeletal and cardiology), citing a JAMA study from that week showing value-based models beat old fee-for-service care, "amplified when we look at two-sided risk." And Vori's Dr. Mary O'Connor flagged that two big quality measures, improving physical health and mental health, get triple-weighted in 2027, while warning that "we're also seeing more health care systems and hospitals saying we're dropping Medicare Advantage contracts."

5. Even Cigna cut the GLP-1 weight-loss drugs its own employees wanted. (Pundit)

On the Across The Bar Podcast (Sept 17), the hosts zeroed in on a telling irony: Cigna, an insurance company, removed GLP-1 coverage from its own employees' health plan, and 450 employees signed a petition to bring it back, each attaching a personal story. Cigna's stated reason was that the drugs are "too expensive" and that "there are other means that are more economical." The hosts' point: if even a company in the insurance business is walking away from the most-requested benefit around, that tells you how the industry is doing the cost math on these drugs.

The Debate: Do Pharma Tariffs Bring Manufacturing Home, or Just Raise Costs?

This was the liveliest disagreement of the week, and both sides showed up.

The case FOR tariffs (as a tool): On Simply Trade (Sept 19), the host argued the U.S. genuinely needs to be able to make its own critical medicines, pointing to "the COVID times where certain pharmaceuticals were not produced in the United States, and we couldn't get them in fast enough for the people who needed them." National security and public health, in this view, are the rare cases where tariffs are justified. And on Molecule to Market (Sept 18), a veteran pharma manufacturing executive said the pressure is already working: the U.S. government "has been most determined to make a change to the existing model... using various tools," and the combination of tariffs and pricing deals is "consequential, I think it will be at least comparable to the impact of the duties discussion." The message companies are hearing: "we make some deals with you regarding pricing. But we expect from you that you move manufacturing into the US."

The case AGAINST tariffs (as the answer): The same Simply Trade host was blunt that a tariff by itself won't do it: "tariffs don't achieve that goal in and of itself. That is a tool that can be used, but there's a whole shed of tools that need to be used in conjunction with that one tool that will entice those pharmaceutical companies to make investments in manufacturing in the United States." The Molecule to Market executive noted much of the factory-building is being "forced by political constraints, not so much because their capacity planning tells them" they need it, i.e., plants built to satisfy policy, not demand, which can be an expensive way to make medicine. And PwC's advisers highlighted the built-in contradiction: because taxpayers foot much of the U.S. drug bill through Medicare and Medicaid, raising import costs partly raises the government's own spending.

Where they agree: this is not a temporary policy. As the Simply Trade host put it, "it's really hard to walk away from billions and billions... of tariff revenue," so regardless of who controls Congress after the midterms, "I don't think we're going to see large scale changes to the tariff landscape."

The Names in Play

Note: several of these read-throughs are thematic; the podcasts discussed the policies and dynamics that hit these insurers, not always the tickers by name.

Read-Throughs

• PBMs (drug middlemen): The Pharmacy Podcast Network (Sept 16) reminded listeners that PBM reform was actually enacted in February 2026. A NACDS leader said flatly that without a united pharmacy lobby, "those reforms would not have been enacted." The next target is a "Main Street Pharmacy Access Act" that cleared a key House committee in May.
• Biosimilars / generics: Watch the tariff fine print. PwC flagged that the 100% duty starts with patented drugs but "there's conversation whether generic products will also be brought into the fold," which would hit the low-cost end of the supply chain hardest.
• Ex-U.S. / China: Big Take Asia (Sept 15) reported that nearly half of global drug licensing deals last year involved Chinese companies, up from just 16% in 2022, with 32 U.S.–China deals already done through July, on track to beat last year's record of 45. Big Pharma is increasingly outsourcing early drug discovery to China; lawmakers in both chambers have introduced bills to scrutinize it.
• Medicaid & exchange insurers: Beyond the Medicaid cliff above, The Seven Figures Or Bust Podcast (Sept 14) covered a brewing ACA-fraud crackdown: on a TV interview, CMS's Dr. Oz claimed roughly 3 million Floridians enrolled in ACA coverage claiming a low-income tier for which only ~636,000 were eligible, "nearly five people enrolled for every one potentially eligible person," and CMS is weighing a moratorium on new ACA sales agents. A cleaner exchange market means fewer (but potentially healthier-mix) members for the insurers that live there.
• Optum-style services & hospitals: UnitedHealth selling its WellMed clinics stake to TPG (Telltales) is a notable trim of the "own-the-doctor" model, even as it fights hospitals on the coverage side. On the hospital side, both Bright Spots and HerMoney flagged systems dropping Medicare Advantage contracts (Mayo Clinic among them) over payment friction and prior authorization.
• GLP-1 exposure: Frequency (Sept 14) reported employers cutting GLP-1 coverage from 72% to 60% in a single year, even as it's the single most-requested benefit, with 2027 employer health costs projected to rise 9.2%–11.1% (the steepest since 2003, and up 76% over the decade). One benefits expert the hosts cited called it an "existential reckoning" over whether employers can keep offering benefits at all. Read that as a demand headwind for Novo Nordisk (NVO) and Lilly (LLY) on the commercial-insurance side.

What Changed

• The pharma tariff goes from talk to reality at end of September, the first time patented imported medicines face a duty at all (0% → 100% for non-exempt companies).
• Medicare Part D premium caps are gone. On HerMoney with Jean Chatzky (Sept 16), Medicare brokers explained that the IRA temporarily capped Part D premium increases (about $35 in year one, $50 in year two), and "this year, there is no limit." The government expects most people to pay no more than ~$20 a month more; the brokers were openly skeptical. Plan choices have already shrunk from 23–26 per area to 7–9.
• PBM reform is now law (February 2026), a shift from "coming" to "here," reframing this year's debate around the next bill rather than the last one.